This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 12
  • /
  • EMA issues advice on use of Paxlovid (PF-07321332 ...

EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19.

Read time: 1 mins
Published:21st Dec 2021
EMA’s human medicines committee (CHMP) has issued advice on the use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19.

The medicine, which is not yet authorised in the EU, can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease. Paxlovid should be administered as soon as possible after diagnosis of COVID-19 and within 5 days of the start of symptoms.

The two active substances of the medicine, PF-07321332 and ritonavir, which are available as separate tablets, should be taken together twice a day for 5 days. EMA issued this advice to support national authorities who may decide on possible early use of the medicine prior to marketing authorisation, for example in emergency use settings, in the light of rising rates of infection and deaths due to COVID-19 across the EU.

The EMA cautioned against use of Paxlovid during pregnancy or in people who can become pregnant and aren't using contraception, citing the potential risks the drug could pose to a fetus.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.